These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 28651374)

  • 1. CD70, a novel target of CAR T-cell therapy for gliomas.
    Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
    Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
    Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
    Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
    Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
    Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
    Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
    [No Abstract]   [Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM
    Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.
    Lertsumitkul L; Iliopoulos M; Wang SS; McArthur SJ; Ebert LM; Davenport AJ; Endersby R; Hansford JR; Drummond KJ; Cross R; Jenkins MR
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39111833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion.
    De Munter S; Buhl JL; De Cock L; Van Parys A; Daneels W; Pascal E; Deseins L; Ingels J; Goetgeluk G; Jansen H; Billiet L; Pille M; Van Duyse J; Bonte S; Vandamme N; Van Dorpe J; Offner F; Leclercq G; Taghon T; Depla E; Tavernier J; Kerre T; Drost J; Vandekerckhove B
    Cancer Immunol Res; 2024 Sep; 12(9):1236-1251. PubMed ID: 38874582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
    Hou AJ; Shih RM; Uy BR; Shafer A; Chang ZL; Comin-Anduix B; Guemes M; Galic Z; Phyu S; Okada H; Grausam KB; Breunig JJ; Brown CE; Nathanson DA; Prins RM; Chen YY
    Neuro Oncol; 2024 Oct; 26(10):1850-1866. PubMed ID: 38982561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
    Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
    Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
    Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
    J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.
    Shaffer DR; Savoldo B; Yi Z; Chow KK; Kakarla S; Spencer DM; Dotti G; Wu MF; Liu H; Kenney S; Gottschalk S
    Blood; 2011 Apr; 117(16):4304-14. PubMed ID: 21304103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
    Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
    J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
    Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
    J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
    Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
    Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
    Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F
    Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.